Table 1.
Clinicopathologic Features of 70 Metastatic Colorectal Cancer Patients Receiving FOLFIRI Plus Bevacizumab Chemotherapy
| Variables | Number (%) |
|---|---|
| Gender | |
| Male/female | 42 (60.0)/28 (40.0) |
| Age (years) (mean ± SD) | 69.0 ± 12.3 |
| Maximum tumor size (cm) | |
| < 5/≥ 5 | 42 (60.0)/28 (40.0) |
| Location | |
| Colon/rectum | 51 (72.9)/19 (27.1) |
| Depth of invasion | |
| T1+ T2/T3+ T4 | 7 (10.0)/63 (90.0) |
| Lymph node metastasis | |
| N(−)/N(+) | 12 (17.1)/58 (82.9) |
| Vascular invasion | |
| Yes/no | 25 (35.7)/45 (64.3) |
| Perineural invasion | |
| Yes/no | 44 (62.9)/26 (37.1) |
| Histology | |
| WD/MD/PD | 6 (8.6)/54 (77.1)/10 (14.3) |
| Response | |
| CR+PR/SD+PD | 51 (72.9)/19 (27.1) |
| Disease control rate | |
| CR+PR+SD/PD | 63 (90.0)/7 (10.0) |
| Metastasectomy | |
| Yes/no | 18 (25.7)/52 (74.3) |
| AE grade 3/4 | |
| Yes/no | 7 (10.0)/63 (90.0) |
WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated.